Gaithersburg-based MedImmune posted earnings ranging from 62 cents to 67 cents per share in the first quarter, up from 23 cents per share in first quarter 2006.
The drug company’s estimates are preliminary and will not be finalized until May 3.
The earnings jump was attributed to improved sales of Synagis, the company’s lung infection drug.
